Tumor Lysis Syndrome in a Low-Risk Pancreatic Cancer Patient
Tumor lysis syndrome (TLS) is the most common hematologic emergency encountered during the treatment of high-grade malignancies. While it can lead to death, the prognosis is typically excellent if caught early on in the course. Risk stratification prior to treatment initiation is paramount in decidi...
Main Authors: | Paul Travers, Alexandra Goodman, Bernard Poiesz |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-09-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/512827 |
Similar Items
-
Diagnosis and management of tumor lysis syndrome.
by: Isha Puri, et al.
Published: (2020-05-01) -
Effectiveness and Safety of Allopurinol, Febuxostat, and Rasburicase in the Prevention of Tumor Lysis Syndrome: A Systematic Review and Network Meta-analysis
by: Ella Mae I. Masamayor, et al.
Published: (2022-07-01) -
Tumor lysis syndrome in pediatric patients with hematological malignancies
by: Lamis Hani Elkhatib, et al.
Published: (2022-01-01) -
Pitfalls of Current Diagnostic Criteria of Tumor Lysis Syndrome
by: Naji Alhamid, et al.
Published: (2024-03-01) -
Spontaneous tumor lysis syndrome occurring in untreated uterine cancer
by: Rachel Berger, et al.
Published: (2017-11-01)